THRD
DelistedTHRD — Post-Mortem
Third Harmonic Bio, Inc. (THRD), focused on therapeutics, faced substantial challenges leading to a voluntary dissolution approved by shareholders on June 5, 2025. Following a detailed Plan of Liquidation, the company filed a Form 25 with the SEC on July 31, 2025, signaling its intention to delist from Nasdaq—a process culminating in liquidation distributions to shareholders, effective on August 10, 2025. The company's formal dissolution was characterized by an orderly wind-down of operations and clear communication of the associated tax implications for its shareholders, emphasizing the importance of regulatory compliance. This marked an end to its public trading activity, entailing significant disenfranchisement for investors reliant on its future prospects.
Third Harmonic Bio, Inc. voluntarily dissolved and delisted from Nasdaq following stockholder approval on June 5, 2025, with a formal Certificate of Dissolution filed on July 31, 2025.
Could I Have Seen This Coming?
No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.
Post-Mortem Analysis
Five-section narrative grounded in primary filings and contemporaneous reporting.
Origin
Formed with the intention of developing innovative therapeutics, Third Harmonic Bio aimed to leverage advancements in biotechnology to improve patient outcomes.
Peak
The company's operational peak was undetermined within the report, as the dissolution process overshadowed performance metrics.
Turning Point
Shareholders approved the Plan of Liquidation at the Annual Meeting on June 5, 2025.
End
The company was officially dissolved when the Certificate of Dissolution was filed on July 31, 2025.
Impact
The voluntary dissolution eliminated shareholder investment in the company, leading to a significant loss of capital for investors and an end to any future returns.
Lessons for Today's Investors
Transferable patterns identified from this case, written as research-report observations.
- 1
Importance of clear communication: Companies must transparently communicate their strategies and financials to avoid stakeholder uncertainty.
- 2
Regulatory compliance is essential: Adhering to SEC regulations ensures proper process in corporate actions such as liquidation and delisting.
- 3
Delisting and liquidation can have significant shareholder implications: Understanding the tax and distribution consequences can affect shareholder satisfaction and trust.
Frequently Asked Questions
What led to Third Harmonic Bio's liquidation?
When did Third Harmonic Bio's delisting become effective?
What tax implications did shareholders face due to the dissolution?
Source Filings
Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.
SEC EDGAR · Form 25Filed Jul 31, 2025
Removed from listing - SEC Form 25 filed.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
Third Harmonic Bio, Inc. filed a Form 8-K on July 31, 2025, to report the voluntary liquidation and dissolution of the company.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
On June 5, 2025, stockholders of Third Harmonic Bio, Inc. approved the Plan of Liquidation and Dissolution at the company's Annual Meeting.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
Third Harmonic Bio, Inc. delivered formal notice to Nasdaq on July 21, 2025, regarding its intention to voluntarily delist its shares.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
The company filed a Form 25 with the SEC on July 31, 2025, to effect the voluntary delisting of its common stock, which will be effective on or about August 10, 2025.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
The Certificate of Dissolution for Third Harmonic Bio, Inc. became effective on July 31, 2025, after being filed with the Secretary of State of Delaware on the same date.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
As of July 31, 2025, Third Harmonic Bio, Inc. instructed its transfer agent to close its stock transfer books and discontinue recording transfers of its common stock.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
The record date for determining stockholders entitled to receive any future distributions of available assets was fixed as July 31, 2025.
SEC EDGAR · Form 8-KFiled Jul 31, 2025
Third Harmonic Bio, Inc. plans to file a Form 15 with the SEC on August 11, 2025, to terminate the registration of its common stock under the Securities Exchange Act.
Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.
Categories:
Industries:
Tags:
Related tickers: